|Dr. George M. Lasezkay Pharma.D., J.D.||Interim CEO & Director||52k||N/A||1952|
|Mr. Charles A. Deignan||Chief Financial Officer||434.36k||N/A||1964|
|Ms. Jenny R. Kobin||Head of Investor Relations||N/A||N/A||1967|
|Mr. Leslie B. Zacks||Gen. Counsel, Chief Compliance Officer & Sec.||N/A||N/A||1969|
|Mr. Rick McElheny||VP of Corp. Devel.||N/A||N/A||N/A|
Clearside Biomedical, Inc., a late-stage clinical biopharmaceutical company, develops pharmacological therapies to restore and preserve vision for people with serious eye diseases. It develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion. The company was founded in 2011 and is headquartered in Alpharetta, Georgia.
Clearside Biomedical, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.